Zaltrap and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Zaltrap (ziv-aflibercept), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Fluorouracil, and have Colorectal cancer metastatic.

The study is created by eHealthMe based on reports of 1,432 people who have side effects when taking Zaltrap from the FDA, and is updated regularly.

What is Zaltrap?

Zaltrap has active ingredients of ziv-aflibercept. eHealthMe is studying from 1,432 Zaltrap users. Check the latest studies of Zaltrap.

On May, 04, 2026

1,432 people reported to have side effects when taking Zaltrap.
Among them, 65 people (4.54%) died.

Among these 65 people:

How long have people been on Zaltrap when they died? *

What is the gender of people who died when taking Zaltrap? *

female: 30 %
male: 70 %

What is the age of people who died when taking Zaltrap? *

What are other drugs people take besides Zaltrap? *

What are other side effects people have before they died? *

Malignant Neoplasm Progression (cancer tumour came back): 5 people, 7.69%
Paronychia (infection in the tissues adjacent to a nail on a finger or toe): 3 people, 4.62%
Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 3 people, 4.62%
Disease Progression: 3 people, 4.62%
Rashes (redness): 3 people, 4.62%
Excessive Or Unwanted Hair In Women: 3 people, 4.62%
Malaise (a feeling of general discomfort or uneasiness): 2 people, 3.08%
Diarrhea: 2 people, 3.08%
Rectal Tenesmus (a feeling of incomplete defecation): 2 people, 3.08%
Metastases To Liver (cancer spreads to liver): 2 people, 3.08%

What are the existing conditions these people have? *

Colorectal Cancer Metastatic (cancer of colon and rectal spreads to other parts): 13 people, 20.00%
Colon Cancer: 10 people, 15.38%
Colon Cancer Metastatic (cancer of colon spreads to other part of body): 5 people, 7.69%
Rectal Cancer (cancer of rectum): 4 people, 6.15%
Rectal Neoplasm (tumour of rectum): 3 people, 4.62%
Rectal Cancer Metastatic (cancer of rectum spreads to other): 2 people, 3.08%
Rectosigmoid Cancer Metastatic (cancer that originates in the rectum and sigmoid colon and spreads to other part): 1 person, 1.54%
Metastasis (spreadable cancer to other organ from origin): 1 person, 1.54%
Disease Progression: 1 person, 1.54%
Colorectal Cancer Stage Iv (cancer of colon and rectal spreads to liver or lung): 1 person, 1.54%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Zaltrap:

Zaltrap (1,432 reports)

Expand to all the drugs that have ingredients of ziv-aflibercept:

Death and drugs with ingredients of ziv-aflibercept (128 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Zaltrap:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,141 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ziv-aflibercept (the active ingredients of Zaltrap) and Zaltrap (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.